Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialBMJ 2001; 322 doi: (Published 16 June 2001) Cite this as: BMJ 2001;322:1456
We have recently been alerted to two small errors in a table in this paper by Michael Rösler and colleagues (1999;318:633-8). In the intention to treat analysis for high dose rivastigmine, the P value versus placebo for the Alzheimer's disease assessment scale (cognitive subscale) should be 0.011 [not <0.1] and for the progression deterioration scale should be 0.07 [not <0.1].
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial